PapersFlow Research Brief
Autoimmune Bullous Skin Diseases
Research Guide
What is Autoimmune Bullous Skin Diseases?
Autoimmune bullous skin diseases are a cluster of disorders characterized by autoantibodies targeting skin adhesion molecules, leading to blistering and erosions, with key examples including bullous pemphigoid and pemphigus vulgaris.
Research on autoimmune bullous skin diseases encompasses 65,870 works focused on pathogenesis, diagnosis, and treatment of pemphigoid diseases such as bullous pemphigoid and pemphigus vulgaris. Key areas include autoantibodies against desmoglein, rituximab therapy, epidemiology, and immunosuppressive approaches like intravenous immunoglobulin. Growth rate over the past five years is not available in the provided data.
Topic Hierarchy
Research Sub-Topics
Bullous Pemphigoid Pathogenesis
This sub-topic investigates the molecular mechanisms underlying autoantibody production against BP180 and BP230 antigens in bullous pemphigoid. Researchers study complement activation, inflammatory cytokine profiles, and eosinophil recruitment in lesional skin.
Pemphigus Vulgaris Desmoglein Autoimmunity
This area examines autoantibodies targeting desmoglein 1 and 3 in pemphigus vulgaris, focusing on acantholysis and epidermal blister formation. Studies explore epitope spreading and B-cell tolerance breakdown.
Rituximab Therapy in Autoimmune Bullous Diseases
Research evaluates rituximab's efficacy in depleting CD20+ B cells for treating refractory pemphigus and pemphigoid. Trials assess dosing regimens, relapse rates, and combination with immunosuppressants.
Epidemiology of Pemphigoid Diseases
This sub-topic analyzes incidence, prevalence, and risk factors like age, comorbidities, and drugs triggering bullous pemphigoid. Population-based studies track geographic variations and temporal trends.
Diagnostic Criteria for Autoimmune Bullous Diseases
Researchers develop and validate immunofluorescence, ELISA, and biopsy-based criteria for distinguishing pemphigoid from pemphigus. Studies focus on non-invasive biomarkers and diagnostic algorithms.
Why It Matters
Autoimmune bullous skin diseases impact patient quality of life through painful blisters and require precise diagnosis for effective management. Rituximab therapy targets autoantibodies in pemphigus vulgaris and bullous pemphigoid, offering remission in refractory cases as noted in studies on immunosuppressive therapy. Epidemiology data aids in identifying at-risk populations, while understanding desmoglein roles informs targeted interventions, reducing reliance on broad immunosuppressants like intravenous immunoglobulin.
Reading Guide
Where to Start
"The 1982 revised criteria for the classification of systemic lupus erythematosus" by Eng M. Tan et al. (1982), as it provides foundational principles for classifying autoimmune diseases relevant to bullous disorders through immunologic criteria.
Key Papers Explained
"The 1982 revised criteria for the classification of systemic lupus erythematosus" by Eng M. Tan et al. (1982) establishes immunologic classification standards applicable to autoantibody-driven bullous diseases. "Nomenclature for factors of the HLA system, 2010" by S. G. E. Marsh et al. (2010) details HLA associations influencing autoimmune susceptibility, linking to desmoglein-targeted pathology. "Psoriasis" by Frank O. Nestlé et al. (2009) connects to overlapping inflammatory skin mechanisms in bullous contexts.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research centers on rituximab and immunosuppressive therapy efficacy in bullous pemphigoid and pemphigus vulgaris, with emphasis on autoantibody dynamics and desmoglein roles. No recent preprints or news available; frontiers involve refining epidemiology and intravenous immunoglobulin protocols based on existing 65,870 works.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | The 1982 revised criteria for the classification of systemic l... | 1982 | Arthritis & Rheumatism | 14.5K | ✕ |
| 2 | Nomenclature for factors of the HLA system, 2010 | 2010 | Tissue Antigens | 4.1K | ✓ |
| 3 | Psoriasis | 2009 | New England Journal of... | 2.7K | ✓ |
| 4 | Standardization of terminology, definitions and outcome criter... | 2008 | Blood | 2.6K | ✓ |
| 5 | M-Type Phospholipase A <sub>2</sub> Receptor as Target Antigen... | 2009 | New England Journal of... | 2.2K | ✓ |
| 6 | Pathogenesis and clinical features of psoriasis | 2007 | The Lancet | 2.1K | ✕ |
| 7 | Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is ... | 2009 | The Journal of Immunology | 2.0K | ✓ |
| 8 | SEROLOGICAL EVIDENCE OF AN ASSOCIATION OF A NOVEL CHLAMYDIA, T... | 1988 | The Lancet | 2.0K | ✕ |
| 9 | Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials | 2014 | New England Journal of... | 1.9K | ✓ |
| 10 | HLA-B*5701 Screening for Hypersensitivity to Abacavir | 2008 | New England Journal of... | 1.8K | ✓ |
Frequently Asked Questions
What are the main diseases in autoimmune bullous skin diseases?
The primary diseases are bullous pemphigoid and pemphigus vulgaris. These involve autoantibodies disrupting skin adhesion, causing subepidermal or intraepidermal blisters. Diagnosis relies on detection of specific autoantibodies and clinical features.
How are autoantibodies involved in these diseases?
Autoantibodies target desmoglein in pemphigus vulgaris and hemidesmosomal proteins in bullous pemphigoid. This leads to loss of keratinocyte adhesion and blister formation. Research emphasizes their role in pathogenesis and as diagnostic markers.
What treatments are used for autoimmune bullous skin diseases?
Rituximab therapy depletes B cells to reduce autoantibody production in bullous pemphigoid and pemphigus. Immunosuppressive therapy and intravenous immunoglobulin control inflammation and achieve remission. These approaches address underlying autoimmune mechanisms.
What is the role of desmoglein in these diseases?
Desmoglein is a desmosomal protein targeted by autoantibodies in pemphigus vulgaris. Autoantibody binding disrupts intercellular adhesion between keratinocytes. This pathology is central to intraepidermal blistering observed in the disease.
How is diagnosis performed for bullous pemphigoid?
Diagnosis involves biopsy showing subepidermal blisters and immunofluorescence detecting IgG autoantibodies at the dermal-epidermal junction. Clinical features include tense bullae in elderly patients. Epidemiology studies support these criteria for accurate classification.
What is the current research focus?
Current focus includes pathogenesis via autoantibodies, rituximab efficacy, and epidemiology of pemphigoid diseases. Studies explore desmoglein in autoimmune mechanisms and immunosuppressive therapy outcomes. The field comprises 65,870 works.
Open Research Questions
- ? How do specific desmoglein autoantibodies initiate acantholysis in pemphigus vulgaris?
- ? What epidemiological factors drive increasing incidence of bullous pemphigoid in aging populations?
- ? Which biomarkers predict response to rituximab in refractory autoimmune bullous diseases?
- ? How does intravenous immunoglobulin modulate autoantibody production in pemphigoid?
- ? What genetic associations beyond HLA influence susceptibility to these diseases?
Recent Trends
The field maintains 65,870 works with no specified five-year growth rate.
Persistent emphasis on autoantibodies, rituximab therapy, desmoglein pathology, and immunosuppressive therapy including intravenous immunoglobulin in bullous pemphigoid and pemphigus vulgaris.
No recent preprints or news reported.
Research Autoimmune Bullous Skin Diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Autoimmune Bullous Skin Diseases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers